FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578164715> ?p ?o ?g. }

• W2578164715 endingPage "349" @default.
• W2578164715 startingPage "307" @default.
• W2578164715 abstract "The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults.The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences. Literature reviews are provided for those pharmacologic agents for which sufficient evidence was available to establish recommendations. The AASM Board of Directors approved the final recommendations.The following recommendations are intended as a guideline for clinicians in choosing a specific pharmacological agent for treatment of chronic insomnia in adults, when such treatment is indicated. Under GRADE, a STRONG recommendation is one that clinicians should, under most circumstances, follow. A WEAK recommendation reflects a lower degree of certainty in the outcome and appropriateness of the patient-care strategy for all patients, but should not be construed as an indication of ineffectiveness. GRADE recommendation strengths do not refer to the magnitude of treatment effects in a particular patient, but rather, to the strength of evidence in published data. Downgrading the quality of evidence for these treatments is predictable in GRADE, due to the funding source for most pharmacological clinical trials and the attendant risk of publication bias; the relatively small number of eligible trials for each individual agent; and the observed heterogeneity in the data. The ultimate judgment regarding propriety of any specific care must be made by the clinician in light of the individual circumstances presented by the patient, available diagnostic tools, accessible treatment options, and resources. We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use zolpidem as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use triazolam as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use temazepam as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use ramelteon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians use doxepin as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use tiagabine as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use diphenhydramine as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use tryptophan as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK). We suggest that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK)." @default.
• W2578164715 created "2017-01-26" @default.
• W2578164715 creator A5009634757 @default.
• W2578164715 creator A5022588225 @default.
• W2578164715 creator A5039315120 @default.
• W2578164715 creator A5042168269 @default.
• W2578164715 creator A5082524917 @default.
• W2578164715 date "2017-02-15" @default.
• W2578164715 modified "2023-10-17" @default.
• W2578164715 title "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline" @default.
• W2578164715 cites W103923181 @default.
• W2578164715 cites W11283495 @default.
• W2578164715 cites W118822196 @default.
• W2578164715 cites W13142413 @default.
• W2578164715 cites W146822938 @default.
• W2578164715 cites W1530494640 @default.
• W2578164715 cites W1532372165 @default.
• W2578164715 cites W15424833 @default.
• W2578164715 cites W1545689369 @default.
• W2578164715 cites W1569813478 @default.
• W2578164715 cites W1574691271 @default.
• W2578164715 cites W1629747952 @default.
• W2578164715 cites W1684861691 @default.
• W2578164715 cites W1762892354 @default.
• W2578164715 cites W182752376 @default.
• W2578164715 cites W185930437 @default.
• W2578164715 cites W1863769327 @default.
• W2578164715 cites W186877966 @default.
• W2578164715 cites W1894555474 @default.
• W2578164715 cites W193681150 @default.
• W2578164715 cites W1937224863 @default.
• W2578164715 cites W1957535368 @default.
• W2578164715 cites W1965130113 @default.
• W2578164715 cites W1967029438 @default.
• W2578164715 cites W1967113132 @default.
• W2578164715 cites W1972998179 @default.
• W2578164715 cites W1974771037 @default.
• W2578164715 cites W1977460854 @default.
• W2578164715 cites W1977894152 @default.
• W2578164715 cites W1978212445 @default.
• W2578164715 cites W1978889676 @default.
• W2578164715 cites W1983263891 @default.
• W2578164715 cites W1985389401 @default.
• W2578164715 cites W1987429320 @default.
• W2578164715 cites W1987459742 @default.
• W2578164715 cites W1987607889 @default.
• W2578164715 cites W1988943101 @default.
• W2578164715 cites W1990413382 @default.
• W2578164715 cites W1990783866 @default.
• W2578164715 cites W1992543303 @default.
• W2578164715 cites W1993788653 @default.
• W2578164715 cites W1999482712 @default.
• W2578164715 cites W2000351842 @default.
• W2578164715 cites W2002669039 @default.
• W2578164715 cites W2002868166 @default.
• W2578164715 cites W2004548153 @default.
• W2578164715 cites W2005326122 @default.
• W2578164715 cites W2005399338 @default.
• W2578164715 cites W2006489842 @default.
• W2578164715 cites W2007027420 @default.
• W2578164715 cites W2007882676 @default.
• W2578164715 cites W2008975248 @default.
• W2578164715 cites W2009221943 @default.
• W2578164715 cites W2009845727 @default.
• W2578164715 cites W2010534854 @default.
• W2578164715 cites W2013099481 @default.
• W2578164715 cites W2014257408 @default.
• W2578164715 cites W2021124523 @default.
• W2578164715 cites W2021403888 @default.
• W2578164715 cites W2023344658 @default.
• W2578164715 cites W2031207549 @default.
• W2578164715 cites W2032887698 @default.
• W2578164715 cites W2035240111 @default.
• W2578164715 cites W2037926687 @default.
• W2578164715 cites W2038344171 @default.
• W2578164715 cites W2038637825 @default.
• W2578164715 cites W2039647336 @default.
• W2578164715 cites W2040657859 @default.
• W2578164715 cites W2040819022 @default.
• W2578164715 cites W2041622156 @default.
• W2578164715 cites W2048722880 @default.
• W2578164715 cites W2050923845 @default.
• W2578164715 cites W2051392321 @default.
• W2578164715 cites W2057014466 @default.
• W2578164715 cites W2057263390 @default.
• W2578164715 cites W2060370838 @default.
• W2578164715 cites W2062350167 @default.
• W2578164715 cites W2064197842 @default.
• W2578164715 cites W2065743497 @default.
• W2578164715 cites W2066588666 @default.
• W2578164715 cites W2068239023 @default.
• W2578164715 cites W2069107021 @default.
• W2578164715 cites W2071327907 @default.
• W2578164715 cites W2071906824 @default.
• W2578164715 cites W2073170620 @default.
• W2578164715 cites W2073280758 @default.
• W2578164715 cites W2073563837 @default.
• W2578164715 cites W2074908833 @default.

• next